2seventy bio, Inc.

NasdaqGS:TSVT Stock Report

Market Cap: US$251.4m

2seventy bio Past Earnings Performance

Past criteria checks 0/6

2seventy bio has been growing earnings at an average annual rate of 2.2%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 8.2% per year.

Key information

2.2%

Earnings growth rate

25.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate8.2%
Return on equity-85.2%
Net Margin-216.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Mar 07
These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Feb 06
2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Jan 17
Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Dec 13
2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

May 05
Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

Mar 21
Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 19
2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

Oct 04
We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

2seventy Bio: This Spinoff In The CAR-T Space Is Attractive

Sep 08

2seventy bio Prospects

Aug 23

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Aug 12
Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

2seventy bio GAAP EPS of -$2.02 misses by $0.09, revenue of $13.48M misses by $3.04M

Aug 10

Revenue & Expenses Breakdown
Beta

How 2seventy bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:TSVT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23100-21869218
30 Sep 23146-184720
30 Jun 23147-180790
31 Mar 23125-215760
31 Dec 2291-25479230
30 Sep 2251-292850
30 Jun 2257-284890
31 Mar 2251-291930
31 Dec 2155-29294223
30 Sep 2148-308910
30 Jun 2148-320900
31 Mar 21150-222920
31 Dec 20248-120910
31 Dec 1944-321820
31 Dec 1855-200540

Quality Earnings: TSVT is currently unprofitable.

Growing Profit Margin: TSVT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TSVT is unprofitable, but has reduced losses over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare TSVT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TSVT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: TSVT has a negative Return on Equity (-85.22%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.